Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Receivables - Net: 2023-2025

Historic Receivables - Net for Phathom Pharmaceuticals (PHAT) over the last 2 years, with Sep 2025 value amounting to $55.8 million.

  • Phathom Pharmaceuticals' Receivables - Net rose 165.01% to $55.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year increase of 165.01%. This contributed to the annual value of $38.8 million for FY2024, which is 2270.01% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Receivables - Net of $55.8 million as of Q3 2025, which was up 8.85% from $51.3 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Receivables - Net high stood at $55.8 million for Q3 2025, and its period low was $1.6 million during Q4 2023.
  • Moreover, its 3-year median value for Receivables - Net was $28.7 million (2024), whereas its average is $27.5 million.
  • Data for Phathom Pharmaceuticals' Receivables - Net shows a peak YoY skyrocketed of 2,270.01% (in 2024) over the last 5 years.
  • Over the past 3 years, Phathom Pharmaceuticals' Receivables - Net (Quarterly) stood at $1.6 million in 2023, then skyrocketed by 2,270.01% to $38.8 million in 2024, then surged by 165.01% to $55.8 million in 2025.
  • Its Receivables - Net was $55.8 million in Q3 2025, compared to $51.3 million in Q2 2025 and $36.4 million in Q1 2025.